Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute leukemia with a normal karyotype and are unrelated to type of previous therapy

Leukemia

Volumn 15, Issue 12, 2001, Pages 1848-1851

  Christiansen, D H ^a   Pedersen Bjergaard, J ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Acute myeloid leukemia; FLT3 internal tandem duplications; MLL internal tandem duplications; Therapy related myelodysplasia; WT1 mutations

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; TYROSINE; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CODON; CONTROLLED STUDY; FEMALE; GENE DUPLICATION; GENE MUTATION; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; PRIORITY JOURNAL; TANDEM REPEAT;

EID: 0035204051     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402246     Document Type: Article

References (28)

1. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia
2. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes Nos. 5 and 7
3. Cytogenetics of secondary myelodysplasia (sMDS) and acute non-lymphocytic leukemia (sANLL)
4. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype
5. Mutations with loss of heterozygosity of p53 are common in therapy-related MDS and AML after exposure to alkylating agents, and significantly associated with deletion or loss of 5q, a complex karyotype and a poor prognosis
6. Increased frequency of dicentric chromosomes in therapy-related MDS and AML compared to de novo disease is significantly related to previous treatment with alkylating agents and suggests a specific susceptibility breakage at the centromere
7. MLL amplification in myeloid leukemias: A study of 14 cases with multiple copies of 11q23
8. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, is closely related to mutation of the TP53 gene and to previous alkylating agents
9. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following cytostatic agents targeting at DNA-topoisomerase II
10. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia
11. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation
12. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors
13. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia
14. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia
15. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines
16. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
17. Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia
18. FLT3 length mutations in AML: Correlation to cytogenetics, FAB-subtype, and prognosis in 652 patients
19. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11
20. ALL-1 partial duplication in acute leukemia
21. The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia
22. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML
23. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics
24. Mutations in the Wilms' tumor gene WT1 in leukemias
25. Mutation analysis of the WT1 gene in sporadic childhood leukaemia
26. Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia
27. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies
28. Wilms' tumor (WTI) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance